Fish-oil supplements for heart and brain: what the big trials found

For most people, an over-the-counter fish-oil capsule does not lower the risk of heart attack, stroke or cardiovascular death, and it does not appear to protect the ageing brain. The clear exception is a high-dose prescription omega-3 drug given to a narrow group of high-risk patients — a result that says more about that drug at that dose than about the supplement aisle.

That gap between the pill on the shelf and the drug in the trial is the whole story, and it is worth setting out carefully, because "omega-3 lowers heart risk" is one of the most confidently marketed claims in nutrition.

The general-population trials came back null

VITAL, published in 2019, randomised 25,871 US adults to 1 gram a day of marine omega-3 or placebo and followed them for a median of 5.3 years [s1]. Major cardiovascular events — a composite of heart attack, stroke and cardiovascular death — occurred at a hazard ratio of 0.92 (95% confidence interval 0.80 to 1.06), a difference statistically indistinguishable from chance [s1]. A secondary signal hinted at fewer heart attacks specifically (hazard ratio 0.72, 95% CI 0.59 to 0.90), but stroke went the other way (1.04, 95% CI 0.83 to 1.31) and death from any cause was unchanged (1.02) [s1].

ASCEND tested the same 1-gram dose in 15,480 people with diabetes but no established cardiovascular disease, over a mean 7.4 years [s3]. First serious vascular events occurred in 8.9% of the fish-oil group and 9.2% of the placebo group — a rate ratio of 0.97 (95% CI 0.87 to 1.08) [s3]. Again, no benefit.

Then REDUCE-IT looked different — with caveats

REDUCE-IT is the trial the industry cites, and it is genuinely positive. It enrolled 8,179 statin-treated patients who had established cardiovascular disease, or diabetes plus risk factors, and a fasting triglyceride level of 135 to 499 mg per decilitre [s2]. They received 4 grams a day of icosapent ethyl — a purified, prescription-only ethyl ester of the omega-3 fatty acid EPA — or placebo, for a median of 4.9 years [s2]. The primary composite endpoint occurred in 17.2% on the drug versus 22.0% on placebo, a hazard ratio of 0.75 (95% CI 0.68 to 0.83), and cardiovascular death fell from 5.2% to 4.3% (hazard ratio 0.80, 95% CI 0.66 to 0.98) [s2].

Two things complicate a simple reading. First, the placebo was mineral oil, which slightly raised LDL cholesterol and inflammatory markers in the comparison group, prompting debate about how much of the benefit was real drug effect versus a worse-off control arm. Second, more patients on the drug were hospitalised for atrial fibrillation or flutter (3.1% versus 2.1%, P=0.004) [s2] — a safety signal that recurs with high-dose omega-3.

The strongest challenge came from STRENGTH, which tested a different 4-gram omega-3 preparation (a carboxylic acid formulation of EPA and DHA) against a corn-oil comparator in 13,078 high-risk patients [s4]. It was halted early for futility: the primary endpoint occurred in 12.0% on omega-3 versus 12.2% on corn oil, a hazard ratio of 0.99 (95% CI 0.90 to 1.09) [s4]. Gastrointestinal side-effects were more common on the omega-3 arm (24.7% versus 14.7%) [s4]. Two high-dose trials, opposite verdicts — which is why the formulation, the dose and the comparator all matter, and why REDUCE-IT does not license a trip to the pharmacy for capsules.

The brain claim is weaker still

Omega-3 is sold as brain food, but the trial evidence for cognition is thin. A Cochrane review of randomised trials in cognitively healthy older adults found no effect on cognitive function: pooled Mini-Mental State Examination scores differed by −0.07 points (95% CI −0.25 to 0.10) across two studies of 3,221 participants, and no trial had even examined whether supplements prevent incident dementia [s5]. The reviewers concluded the supplements were well tolerated but showed no cognitive benefit [s5].

How to read it

An American Heart Association science advisory drew the practical line: routine omega-3 supplementation is not recommended to prevent cardiovascular disease in the general population, though treatment may be reasonable for selected patients with recent heart attack or heart failure [s6]. That is a statement about specific clinical situations, not a general endorsement.

The honest summary is that eating fish is not the same as swallowing fish oil, and a positive drug trial at 4 grams a day is not evidence for a 1-gram capsule bought off a shelf. This is the recurring shape of supplement evidence, visible across vitamin D in healthy adults and the multivitamin: a plausible mechanism, heavy marketing, and randomised trials that mostly fail to deliver. Where omega-3 as a drug does earn its keep, it does so inside the same logic as the numbers on a standard lipid panel and the trials behind them — a prescription decision, not a grocery one. None of this is medical advice, and anyone on omega-3 for a diagnosed condition should not read a null primary-prevention trial as a reason to stop.

Sources

• Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer (VITAL) — New England Journal of Medicine, 2019
• Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT) — New England Journal of Medicine, 2019
• Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus (ASCEND) — New England Journal of Medicine, 2018
• Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events (STRENGTH) — JAMA, 2020
• Omega-3 fatty acid for the prevention of cognitive decline and dementia — Cochrane Database of Systematic Reviews, 2012
• Omega-3 (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease — Circulation (AHA Science Advisory), 2017